Corticotropin-releasing factor reduces tumor volume, halts further growth, and enhances the effect of chemotherapy in 4T1 mammary carcinoma in mice

Tumour Biol. 2014 Feb;35(2):1365-70. doi: 10.1007/s13277-013-1186-0. Epub 2013 Sep 18.

Abstract

The present study examines the effect of the endogenous neuroendocrine factor, corticotropin-releasing factor (CRF), alone or in combination with 5-fluorouracil (5-FU), on 4T1 mammary tumor cells in vitro and in vivo. CRF has been detected in breast cancer tissues; however, the biological effects reported in the literature are sparse and variable. We found that exogenously administered CRF significantly reduced tumor growth without influencing angiogenesis or cell death. Furthermore, CRF reduced tumor interstitial fluid pressure (Pif) and potentiated the effect of 5-FU. These results show that CRF has antitumor effect on mammary carcinoma in mice.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Corticotropin-Releasing Hormone / administration & dosage*
  • Female
  • Fluorouracil / administration & dosage*
  • Humans
  • Mammary Neoplasms, Animal / drug therapy*
  • Mammary Neoplasms, Animal / genetics
  • Mammary Neoplasms, Animal / pathology
  • Mice
  • Neovascularization, Pathologic

Substances

  • Corticotropin-Releasing Hormone
  • Fluorouracil